Truist Financial Corp acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 23,313 shares of the company’s stock, valued at approximately $327,000.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Captrust Financial Advisors lifted its stake in Maravai LifeSciences by 1.3% during the 1st quarter. Captrust Financial Advisors now owns 33,535 shares of the company’s stock valued at $1,183,000 after acquiring an additional 442 shares during the period. Zions Bancorporation N.A. purchased a new stake in Maravai LifeSciences during the first quarter worth $28,000. Arizona State Retirement System grew its position in Maravai LifeSciences by 2.7% during the first quarter. Arizona State Retirement System now owns 32,397 shares of the company’s stock valued at $454,000 after buying an additional 848 shares during the period. Xponance Inc. increased its holdings in Maravai LifeSciences by 7.4% in the first quarter. Xponance Inc. now owns 15,533 shares of the company’s stock valued at $218,000 after buying an additional 1,070 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its position in shares of Maravai LifeSciences by 2.1% in the fourth quarter. Public Employees Retirement System of Ohio now owns 56,289 shares of the company’s stock worth $805,000 after acquiring an additional 1,181 shares during the period. 50.62% of the stock is currently owned by institutional investors and hedge funds.
Maravai LifeSciences Stock Up 2.8 %
MRVI stock opened at $10.40 on Friday. The company has a current ratio of 9.33, a quick ratio of 8.70 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average of $11.79 and a two-hundred day moving average of $13.22. Maravai LifeSciences Holdings, Inc. has a 12 month low of $9.20 and a 12 month high of $26.55. The company has a market cap of $2.61 billion, a price-to-earnings ratio of 18.25 and a beta of -0.26.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on MRVI. Morgan Stanley dropped their target price on Maravai LifeSciences from $27.00 to $12.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 9th. Stifel Nicolaus decreased their target price on Maravai LifeSciences from $17.00 to $12.00 in a research report on Tuesday, August 8th. KeyCorp lowered shares of Maravai LifeSciences from an “overweight” rating to a “sector weight” rating in a report on Tuesday, August 8th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Maravai LifeSciences from $23.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Finally, Bank of America cut their target price on shares of Maravai LifeSciences from $15.00 to $12.00 in a research note on Tuesday, August 8th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.10.
Read Our Latest Stock Analysis on Maravai LifeSciences
Maravai LifeSciences Profile
(Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
Get This Free Report
Source: marketbeat.com
Truist Financial Corp acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 23,313 shares of the company’s stock, valued at approximately $327,000.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Captrust Financial Advisors lifted its stake in Maravai LifeSciences by 1.3% during the 1st quarter. Captrust Financial Advisors now owns 33,535 shares of the company’s stock valued at $1,183,000 after acquiring an additional 442 shares during the period. Zions Bancorporation N.A. purchased a new stake in Maravai LifeSciences during the first quarter worth $28,000. Arizona State Retirement System grew its position in Maravai LifeSciences by 2.7% during the first quarter. Arizona State Retirement System now owns 32,397 shares of the company’s stock valued at $454,000 after buying an additional 848 shares during the period. Xponance Inc. increased its holdings in Maravai LifeSciences by 7.4% in the first quarter. Xponance Inc. now owns 15,533 shares of the company’s stock valued at $218,000 after buying an additional 1,070 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its position in shares of Maravai LifeSciences by 2.1% in the fourth quarter. Public Employees Retirement System of Ohio now owns 56,289 shares of the company’s stock worth $805,000 after acquiring an additional 1,181 shares during the period. 50.62% of the stock is currently owned by institutional investors and hedge funds.
Maravai LifeSciences Stock Up 2.8 %
MRVI stock opened at $10.40 on Friday. The company has a current ratio of 9.33, a quick ratio of 8.70 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average of $11.79 and a two-hundred day moving average of $13.22. Maravai LifeSciences Holdings, Inc. has a 12 month low of $9.20 and a 12 month high of $26.55. The company has a market cap of $2.61 billion, a price-to-earnings ratio of 18.25 and a beta of -0.26.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on MRVI. Morgan Stanley dropped their target price on Maravai LifeSciences from $27.00 to $12.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 9th. Stifel Nicolaus decreased their target price on Maravai LifeSciences from $17.00 to $12.00 in a research report on Tuesday, August 8th. KeyCorp lowered shares of Maravai LifeSciences from an “overweight” rating to a “sector weight” rating in a report on Tuesday, August 8th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Maravai LifeSciences from $23.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Finally, Bank of America cut their target price on shares of Maravai LifeSciences from $15.00 to $12.00 in a research note on Tuesday, August 8th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.10.
Read Our Latest Stock Analysis on Maravai LifeSciences
Maravai LifeSciences Profile
(Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
Get This Free Report
Source: marketbeat.com
